Shijiazhuang Yiling Pharmaceutical (002603.SZ): Withdrawal of the application for clinical trials of "G201-Na Capsules" medication.
Lingyun Pharmaceuticals (002603.SZ) announced that the company will follow the relevant drug approval policies and combine them with the progress of its research projects...
Shijiazhuang Yiling Pharmaceutical (002603.SZ) announced that, based on the relevant policies of drug approval and the progress of research projects, the company has decided, after careful consideration, to apply to the National Medical Products Administration (hereinafter referred to as "NMPA") to withdraw the clinical trial application for the drug "G201-Na Capsules" for the indication of "assisted reproduction". Recently, the company received the "Notice of Termination of Drug Registration Application" issued by the NMPA.
Related Articles
New Stock News | CNGR Advanced Material (300919.SZ) updated its application materials on October 23rd and has already passed the hearing at the Hong Kong Stock Exchange at the beginning of the month.
Qinghua Holdings (08082) issued 20.9 million shares due to the exercise of stock purchase rights.
CIMC ENRIC (03899): CIMC Safeway Technologies (301559.SZ) recorded a net profit attributable to the parent company of 99.5575 million yuan in the first three quarters, a year-on-year decrease of 44.73%.
New Stock News | CNGR Advanced Material (300919.SZ) updated its application materials on October 23rd and has already passed the hearing at the Hong Kong Stock Exchange at the beginning of the month.
Qinghua Holdings (08082) issued 20.9 million shares due to the exercise of stock purchase rights.
CIMC ENRIC (03899): CIMC Safeway Technologies (301559.SZ) recorded a net profit attributable to the parent company of 99.5575 million yuan in the first three quarters, a year-on-year decrease of 44.73%.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
